



Department of Medical Laboratory Science and Biotechnology,
College of Medicine, National Cheng Kung University
Tainan, Taiwan, 701 R. O. C.
TEL:886-6-2353535-5781 FAX:886-6-2363956

Professor Chung-Liang Ho

E-mail: clh9@mail.ncku.edu.tw



Education

1991.9 ~ 1997.8 Ph.D. Columbia University, New York City

1983.9 ~ 1990.6 M.D. National Taiwan University

Research

* An integrated bioinformatic and biomedical approach for cancer research.

* New tumor markers for molecular pathology.

Selected Publications

- * Hsu CC, Chiang CW, Cheng HC, Chang WT, Chou CY, Tsai HW, Lee CT, Wu ZH, Lee TY, Chao A, Chow NH, *Ho CL (corresponding). Identifying LRR16B as an oncofetal gene with transforming enhancing capability using a combined bioinformatics and experimental approach. *Oncogene*. 2011 Feb 10;30(6):654-67.
- * Yeh YM, Chen YL, Cheng HY, Su WC, Chow NH, *Chen TY, *Ho CL (co-corresponding). High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera. *Am J Clin Pathol*. 2010 Aug; 134(2) 266-70.
- * Chen YL, Su IJ, Cheng HY, Chang KC, Lu CC, Chow NH, *Ho CL (co-corresponding), *Huang W. BIOMED-2 protocols to detect clonal immunoglobulin and T cell receptor gene rearrangements in B- and T-cell lymphomas in Southern Taiwan. *Leuk Lymphoma*. 2010 Apr;51(4):650-5.
- * Yen KH, *Ho CL (corresponding), Lee C. The analysis of inconsistencies between cytogenetic annotations and sequence mapping by defining the imprecision zones of cytogenetic banding. *Bioinformatics*. 2009 Apr 1;25(7):845-52.
- * Tsai HW, Chow NH, Lin CP, Chan SH, Chou CY, *Ho CL (corresponding). The significance of prohibitin and c-Met/HGFR expressions in the progression of cervical adenocarcinoma. *Human Pathology*. 2006 Feb; 37(2):198-204.
- * Yen KH, Lee C, Liu HS, *Ho CL (corresponding). A precise and scalable method for querying genes in chromosomal banding regions based on cytogenetic annotations. *Bioinformatics*. 2005 Sep; 1(17):3469-74.
- * Pohl G, Ho CL (equal contribution), Kurman RJ, Bristow R, Wang TL, *Shih IeM. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. *Cancer Research*. 2005 Mar; 65(5):1994-2000.
- * Ho CL, Kurman RJ, Dehari R, Wang TL, *Shih IeM. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. *Cancer Research*. 2004 Oct; 64(19):6915-8.
- * Wang L, C.-L. Ho, D. Sun, R.K. Liem, A. Brown. Rapid movement of axonal neurofilaments interrupted by prolonged pauses. *Nature Cell Biology*. 2000. Mar; 2(3):137-41.